Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Boston Biomedical, Inc.

Shingo Tojo

Hitoshi Ban

Manabu Kusagi

Futoshi Hasegawa

Miki Hashizume

Chiang Jia Li

Yoshiaki Isobe

Hiroki Yamaguchi

Toshio Kanai

Yosuke Takanashi

Daisuke Urabe

Katsunori Tsuboi

Hiroaki Fujiwara

Katsumi Kubota

Eiji Ideue

Nobuyuki Sawada

Eiji Sugaru

Tsuguteru Otsubo

Tomohiro Kodama

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1') wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014; wherein Ris hydrogen atom or Calkyl group, etc.; ring Qis 5- to 10-membered heteroaryl group, etc.; Wis optionally-substituted Calkylene group, etc.; n is 1, 2, 3, 4, or 5; Ris independently halogen atom, optionally-substituted Calkyl group, etc.; Ris hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent. 

1,4-disubstituted imidazole derivative

The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Qrepresents a Caryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R, independently when multiple, represent(s) a halogen atom or the like; Rand Rindependently represent a hydrogen atom or the like; Wrepresents a Calkylene group (said group may be substituted by 1-3 fluorine atoms or Ccycloalkyls); Wrepresents &#x2014;NRC(O)&#x2014; or the like (where Rrepresents a hydrogen atom or Calkyl group); and ring Qrepresents a Carylgroup or the like] 

Imidazolylamide derivative

The present invention relates to a substituted purine derivative of formula (1) wherein Ris alkoxy or the like, Ris alkyl or the like, Ring Qis aryl or the like, Wis alkylene or the like, Ring Qis aromatic carbocyclyl or the like, n is 1-4, Ris hydrogen atom or the like, Xis single bond or the like, Wis alkylene or the like, and Ris hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease. 

Substituted purine derivative

Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, Ris optionally substituted heteroaryl etc.; Ris hydrogen etc.; Rand Rare each independently hydrogen etc., Ris the following group: (wherein Y is optionally substituted five membered heteroaryl etc., Ris optionally substituted aryl etc., Rand Rare each dependently hydrogen etc., and m is the integral 0 etc.) etc.; Ris hydrogen etc.; and Ris hydrogen etc. 

Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative

Growing community of inventors

Osaka, Japan

Shingo Tojo